UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2012
Commission File Number: 001-34949
___________________
Tekmira Pharmaceuticals Corporation
(Translation of registrant's name into English)
100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada, V5J 5J8
(Address of principal executive offices)
___________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F R Form 40-F £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) £
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Tekmira Pharmaceuticals Corporation
|
||
|
Date: June 27, 2012
|
By: |
/s/ IAN C. MORTIMER
|
| Name: |
Ian C. Mortimer
|
|
| Title: |
Executive Vice President, Finance and Chief Financial Officer
|
|
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
|
99.1
|
|
Report of Voting Results
|
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
OF
TEKMIRA PHARMACEUTICALS CORPORATION
(THE “COMPANY”) HELD ON JUNE 20, 2012
REPORT OF VOTING RESULTS
National Instrument 51-102 – Continuous Disclosure Obligations (Section 11.3)
The following matters were put to a vote by a show of hands at the annual and special meeting of the Company:
|
Outcome of Vote
|
|
|
1. The election of the following nominees as directors of the Company for the ensuing year or until their successors are elected or appointed:
|
Carried
|
|
Michael Abrams
Kenneth Galbraith
Don Jewell
Frank Karbe
Daniel Kisner
Mark J. Murray
|
|
|
2. The appointment of KPMG LLP as auditor of the Company for the ensuing year.
|
Carried
|
|
3. Resolution of shareholders of the Company approving the amendment to the Company’s omnibus share compensation plan to increase from 1,643,144 to 2,193,870 common shares in respect of which awards may be granted thereunder.
|
Carried
|
DATED the 22nd day of June, 2012.
TEKMIRA PHARMACEUTICALS CORPORATION
By: /s/ R. Hector MacKay-Dunn
R. Hector MacKay-Dunn, Q.C.
Corporate Secretary